Role of combination antiviral therapy in pandemic influenza and stockpiling implications

BMJ

Volumn 334, Issue 7588, 2007, Pages 293-294

  Tsiodras, Sotirios ^a   Mooney, John D ^b   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b South West Public Health Training Programme ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PROTEIN INHIBITOR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG SENSITIVITY; ECONOMIC ASPECT; HEALTH CARE PERSONNEL; HUMAN; INFLUENZA; LONG TERM CARE; PANDEMIC; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; TREATMENT FAILURE; VIRUS STRAIN; COST; DRUG COMBINATION; DRUG STORAGE; ECONOMICS; EPIDEMIC; REVIEW;

ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; DISEASE OUTBREAKS; DRUG COMBINATIONS; DRUG STORAGE; HUMANS; INFLUENZA, HUMAN;

EID: 33847154534     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39105.428981.BE     Document Type: Review

References (25)

1. Monto AS. The role of antivirals in the control of influenza. Vaccine 2003; 21: 1796-1800.
2. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580-4.
3. World Health Organization. WHO pandemic influenza draft protocol for rapid response and containment. 17 March 2006. www.who.int/csr/disease/avian_influenza/guidelines/pandemicfluprotocol_17.03a.pdf
4. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30.
5. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188: 57-61.
6. Fleming DM. Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract 2001; 55: 189-95.
7. Bright RA, Medina M, Xu X, Perez-Oronoz G, Wallis TR, Davis XM,, et al Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
8. Centers for Disease Control and Prevention. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005-06 influenza season. www.cdc.gov/flu/han011406.htm
9. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430-5.
10. Ziegler T, Hemphill M, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW,, et al Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935-9.
11. Tumpey TM, Garcia-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P,, et al Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci 2002; 99: 13849-54.
12. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. JAMA 1979; 241: 1003-7.
13. Garten RJ, Smith C, Xu X, Balish A, Klimov A, Lien P,, et al Analysis of H5N1 influenza viruses from humans and birds between 2003 and 2005 reveals an increase in the spectrum of viruses with pandemic potential. Abstract 64. Fifth International Conference on Emerging Infectious Diseases, 2006. www.iceid.org/documents/AbstractsFinal.pdf
14. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11: 1515-21.
15. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, Zhang J,, et al Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-9.
16. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818-27.
17. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K,, et al Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759-65.
18. De Jong MD, Thanh TT, Khanh TH, Vo MH, Smith GJ, Nguyen VC,, et al Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-72.
19. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70: 121-31.
20. Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004; 48: 4855-63.
21. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989; 11: 27-40.
22. WHO. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus, 2006. www.who.int/medicines/publications/WHO_PSM_PAR_2006.6.pdf
23. De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB,, et al Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203-7.
24. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43: 199-205.
25. Scholtissek C, Webster RG. Long-term stability of the anti-influenza A compounds—amantadine and rimantadine. Antiviral Res 1998; 38: 213-5.